Navigation Links
Piggy-backing proteins ride white blood cells to wipe out metastasizing cancer
Date:1/6/2014

ITHACA, N.Y. Cornell biomedical engineers have discovered a new way to destroy metastasizing cancer cells traveling through the bloodstream lethal invaders that are linked to almost all cancer deaths by hitching cancer-killing proteins along for a ride on life-saving white blood cells.

"These circulating cancer cells are doomed," said Michael King, Cornell professor of biomedical engineering and the study's senior author. "About 90 percent of cancer deaths are related to metastases, but now we've found a way to dispatch an army of killer white blood cells that cause apoptosis the cancer cell's own death obliterating them from the bloodstream. When surrounded by these guys, it becomes nearly impossible for the cancer cell to escape."

Metastasis is the spread of a cancer cells to other parts of the body. Surgery and radiation are effective at treating primary tumors, but difficulty in detecting metastatic cancer cells has made treatment of the spreading cancers problematic, say the scientists.

King and his colleagues injected human blood samples, and later mice, with two proteins: E-selectin (an adhesive) and TRAIL (Tumor Necrosis Factor Related Apoptosis-Inducing Ligand). The TRAIL protein joined with the E-selectin protein was able to stick to leukocytes white blood cells abundant in the bloodstream. When a cancer cell comes into contact with TRAIL, which is nearly unavoidable in the frenzied flow of blood, the cancer cell essentially kills itself.

"The mechanism is surprising and unexpected in that this repurposing of white blood cells in flowing blood is more effective than directly targeting the cancer cells with liposomes or soluble protein," say the authors.

In the laboratory, King and his colleagues tested this concept's efficacy.

When treating cancer cells with the proteins in saline, they found a 60 percent success rate in killing the cancer cells. In normal laboratory conditions, the saline lacks white blood cells to serve as a carrier for the adhesive and killer proteins. Once the proteins were added to flowing blood that mimicked human-body conditions, however, the success rate in killing the cancer cells jumped to nearly 100 percent.

The study, "TRAIL-Coated Leukocytes that Kill Cancer Cells in the Circulation," was published online today in the journal Proceedings of the National Academy of Sciences.


'/>"/>

Contact: Melissa Osgood
mmo59@cornell.edu
607-255-2059
Cornell University
Source:Eurekalert

Related biology technology :

1. The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry
2. Multipotent Stem Cell Proteins Support Soft Tissue Regeneration
3. Multipotent Stem Cell Proteins Support Rejuvenation While Inhibiting Skin Cancer
4. Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells Industry Trend: Worldwide Industry Latest Market Share, Investment Trends, Growth, Size, Strategy
5. Chemists develop innovative nano-sensors for multiple proteins
6. Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors
7. Tenfold boost in ability to pinpoint proteins in cancer cells
8. Waters Unveils Industrys First Integrated LC/MS Platform for Proteins, Peptides, and Glycans Analysis at WCBP 2013
9. Intrinsically disordered proteins: A conversation with Rohit Pappu
10. Frost & Sullivan Recognizes MicroProtein Technologies for its Path-Breaking Production Technology for Recombinant Proteins in Bacteria
11. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... UCHealth ( Aurora, Colorado ) ... nodule patient management. In addition to optimizing care coordination ... the lung, UCHealth looks to improve provider workflow by ... Stephanie Brown, RN , Thoracic Nurse Navigator, ... an Excel spreadsheet, which was extremely arduous and susceptible ...
(Date:2/16/2017)... Pa. , Feb. 16, 2017  Windtree ... biotechnology company focusing on developing aerosolized KL4 surfactant ... from a preclinical influenza study showed that aerosolized ... survival in a well-established preclinical animal model. The ... a growing body of evidence that supports the ...
(Date:2/15/2017)... ... February 15, 2017 , ... Executive search ... Commercial Officer with GenePeeks. Matt is a veteran life sciences and molecular ... genomics company focused on identifying inherited disease risk in future generations. In his ...
(Date:2/15/2017)... 15, 2017  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... the fourth quarter and full year ended December ... year for Vanda as we continued to demonstrate ... long-term exclusivity for Fanapt," said Mihael H. Polymeropoulos, ... emerging pipeline with important 2017 milestones underscores Vanda,s ...
Breaking Biology Technology:
(Date:2/8/2017)... Feb. 7, 2017 The biometrics market ... the confluence of organizations, desires to better authenticate ... systems (password and challenge questions), biometrics is quickly ... systems. The market is driven by use cases, ... consumer and enterprise uses cases, with consumer-facing use ...
(Date:2/7/2017)... , Feb. 7, 2017 Zimmer Biomet Holdings, ... musculoskeletal healthcare, will present at the LEERINK Partners 6th ... Palace Hotel on Wednesday, February 15, 2017 at 10 ... of the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh ... the conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/3/2017)... SAN ANTONIO , Feb. 3, 2017  Texas Biomedical ... Dr. Larry Schlesinger as the Institute,s ... of Texas Biomed effective May 31, 2017. He is currently ... and Director of the Center for Microbial Interface Biology at ... Dr. Schlesinger as the new President and CEO of Texas ...
Breaking Biology News(10 mins):